falseD02 XH020001613103Medtronic plc 0001613103 2019-09-24 2019-09-24 0001613103 mdt:SeniorNotes2019Due20311.625PercentMember 2019-09-24 2019-09-24 0001613103 mdt:SeniorNotes2019Due2021FloatingMember 2019-09-24 2019-09-24 0001613103 mdt:SeniorNotes2019Due2049Member 2019-09-24 2019-09-24 0001613103 mdt:SeniorNotes2019Due2021Member 2019-09-24 2019-09-24 0001613103 mdt:SeniorNotes2019Due2025Member 2019-09-24 2019-09-24 0001613103 mdt:SeniorNotes2019Due20392.250PercentMember 2019-09-24 2019-09-24 0001613103 us-gaap:CommonStockMember 2019-09-24 2019-09-24 0001613103 mdt:SeniorNotes2019Due2027Member 2019-09-24 2019-09-24 0001613103 mdt:SeniorNotes2019Due20311.00PercentMember 2019-09-24 2019-09-24 0001613103 mdt:SeniorNotes2019Due20391.50PercentMember 2019-09-24 2019-09-24 0001613103 mdt:SeniorNotes2019Due20230.375PercentMember 2019-09-24 2019-09-24 0001613103 mdt:SeniorNotes2019Due2022Member 2019-09-24 2019-09-24

Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 24, 2019
Medtronic Public Limited Company
(Exact name of Registrant as Specified in its Charter)
(State or other jurisdiction
of incorporation)
File Number)
(IRS Employer
Identification No.)

20 On Hatch, Lower Hatch Street
Dublin 2, Ireland
(Address of principal executive offices) (Zip Code)
+353 1 438-1700
(Registrant’s telephone number, including area code)
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Ordinary shares, par value $0.0001 per share
New York Stock Exchange
Floating Rate Notes due 2021
New York Stock Exchange
0.000% Senior Notes due 2021
New York Stock Exchange
0.000% Senior Notes due 2022
New York Stock Exchange
0.375% Senior Notes due 2023
New York Stock Exchange
0.25% Senior Notes due 2025
New York Stock Exchange
1.125% Senior Notes due 2027
New York Stock Exchange
1.625% Senior Notes due 2031
New York Stock Exchange
1.00% Senior Notes due 2031
New York Stock Exchange
2.250% Senior Notes due 2039
New York Stock Exchange
1.50% Senior Notes due 2039
New York Stock Exchange
1.75% Senior Notes due 2049
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01.
Regulation FD Disclosure.

As previously announced, Medtronic plc (the “Company”) today will host a Robotic-Assisted Surgery (RAS) Investor Update in Hartford, Conn., for analysts and investors from 2:00 p.m. to approximately 5:30 p.m. Eastern Daylight Time.

Medtronic will host a live audio webcast of the RAS Investor Update today which, along with slides, can be accessed by clicking on the Investor Events link at on September 24, 2019. An archived audio file will be available for replay on the same webpage later in the day and will be available for approximately twelve months.

The Investor Update will include a RAS prostatectomy procedure performed in a cadaveric lab as part of the Medtronic Minimally Invasive Therapy Group’s ongoing development and testing process of its RAS technology, as well as a short procedure overview with pre-recorded video from a recent cadaveric procedure that was also part of the Company’s ongoing development and testing process. Medtronic’s RAS technology is currently under development. Participants should not infer indications for use. The system is not cleared or approved in any market and is not available for sale or clinical use. In addition, the update will include remarks and responses to audience questions from a panel of surgeons and Medtronic management. Management Q&A is scheduled to begin at approximately 4:15 p.m. Eastern Daylight Time, or shortly thereafter. All procedure footage will be narrated.

The investigational system that will be shown in the update includes a tower, surgeon console, surgical end effectors, and robotic arm carts. The objective of the tower design is to provide a solution that is (1) universal (both RAS and laparoscopic applications), (2) upgradeable, and (3) modular. The surgeon console design aims to provide (1) an open architecture and (2) a three-dimensional, high-definition visualization. The surgical end effector design aims to (1) take advantage of the expertise, know-how, and IP of our existing MITG surgical instrumentation portfolio, and (2) use across a broad spectrum of surgical procedures. The robotic arm cart design aims to provide a solution that is (1) modular and portable, (2) allows for flexible positioning (use one or up to four arms), and (3) uses Medtronic end effectors.

Medtronic’s robotic-assisted surgical system is an investigational device currently under development. Safety and effectiveness of the system has not been established. The system is not cleared or approved in any market and is not available for sale or clinical use.

Figure 1. Medtronic’s RAS system components from left to right: Tower, Surgeon Console, and Robotic Arm Carts
Figure 2. Surgical end effectors
Figure 3. Pedal controls on Surgeon Console
Figure 4. Bird's eye view of robotic arms
Figure 5. Suturing with wristed end effectors
Figure 6. Dissection with electrosurgical end effector
Figure 7. Grasping and dissecting tissue with wristed end effectors

This Current Report on Form 8-K contains forward-looking statements that are not historical in nature. Such forward-looking statements are subject to risks and uncertainties, including the risks related to the RAS system and its development and acceptance in the marketplace, risks related to Medtronic’s use and development of intellectual property, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation and general economic conditions and other risks and uncertainties described in Medtronic plc’s periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of Medtronic plc, as filed with the U.S. Securities and Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ Bradley E. Lerman
Date: September 24, 2019
Bradley E. Lerman
Senior Vice President, General Counsel and Corporate Security